Fully integrated dual YAG/SLT ophthalmic laser system with associated accessories
| Agency: | HEALTH AND HUMAN SERVICES, DEPARTMENT OF |
|---|---|
| State: | Maryland |
| Type of Government: | Federal |
| FSC Category: |
|
| NAICS Category: |
|
| Set Aside: | No Set aside used |
| Posted Date: | May 13, 2026 |
| Due Date: | May 23, 2026 |
| Solicitation No: | 75N98026Q00353 |
| Original Source: | Please Login to View Page |
| Contact information: | Please Login to View Page |
| Bid Documents: | Please Login to View Page |
Description
APEX Accelerators are an official government contracting resource for small businesses. Find your local APEX Accelerator (opens in new window) for free government expertise related to contract opportunities.
APEX Accelerators are funded in part through a cooperative agreement with the Department of Defense.
The APEX Accelerators program was formerly known as the Procurement Technical Assistance Program (opens in new window) (PTAP).
- Contract Opportunity Type: Presolicitation (Original)
- Original Published Date: May 13, 2026 02:52 pm EDT
- Original Response Date: May 23, 2026 09:00 am EDT
- Inactive Policy: Manual
- Original Inactive Date: May 24, 2026
-
Initiative:
- None
- Original Set Aside: No Set aside used
- Product Service Code: 6505 - DRUGS AND BIOLOGICALS
-
NAICS Code:
- 325414 - Biological Product (except Diagnostic) Manufacturing
-
Place of Performance:
Bethesda , MD 20892USA
Statement of Need and Purpose:
This acquisition is necessary to provide supplies and reagents to the Neurodegenerative
Diseases Research Section for neurodegenerative disease research for proteomic analyses.
2. Background Information and Objective:
Our project is focused on advancing our understanding of neurodegenerative diseases,
particularly parkinsonism syndromes, through detailed analyses of human samples using
state-of-the-art Olink Explore assays. By leveraging these assays, we will perform highresolution
proteomics to map protein expression profiles across samples obtained from
patients, thereby illuminating the complex molecular landscape of neurodegeneration.
3. Generic Name of Product:
Human Olink Explore HT Assay Kit
4. Purchase Description:
Item Description Cat no Quantity Total Cost
Olink Explore HT Reagent Kit 98100 3 @ $68,800 ea $206,400.00
Shipping and Handling 0001-Shipping 1 @ $461.31 $461.31
Order Total $206,861.31
5. Salient characteristics.
All deliverables required under this contract shall be packaged, marked, and shipped in
accordance with Government specifications. At a minimum, all deliverables shall be marked
with the contract number and the Contractor's name. The Contractor shall guarantee that all
required materials shall be delivered in an immediately usable and acceptable condition.
The vendor must be able to provide these specifications:
• Must use an antibody-based approach to map protein abundance levels within samples.
• Must provide the abundance levels for thousands of proteins within the samples.
• Must be able to provide data that can be mapped to human biological pathways and
processes that are potentially targetable by therapeutics.
6. Quantity:
Item Description Cat no Quantity Total Cost
Olink Explore HT Reagent Kit 98100 3 @ $68,800 ea $206,400.00
Shipping and Handling 0001-Shipping 1 @ $461.31 $461.31
Order Total $206,861.31
- 6011 EXECUTIVE BLVD., SUITE 503L
- BETHESDA , MD 20892
- USA
- Vishnuvajjala Hanumanth Rao
- vishnuh@mail.nih.gov
- May 13, 2026 02:52 pm EDTPresolicitation (Original)
See Also
Follow Equipment : MRIs System Upgrade Active Contract Opportunity Notice ID 75N98026Q01246 Related
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Due by 9/23/2026
Follow Notice of Intent to Sole Source - Stryker Sales, LLC. Active Contract
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Follow Pre-Solicitation Notice of Intent to Sole-Source Active Contract Opportunity Notice ID NB644050-26-02065
COMMERCE, DEPARTMENT OF
Due by 9/24/2026
Follow Federal Occupational Health - Medications, Vaccines, and Medical Supplies (MVMS) Active Contract
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Due by 9/25/2026